Publication:
A Systematic Review of the Definitions, Determinants, and Clinical Outcomes of Antimicrobial De-escalation in the Intensive Care Unit.

dc.contributor.authorTabah, Alexis
dc.contributor.authorCotta, Menino Osbert
dc.contributor.authorGarnacho-Montero, Jose
dc.contributor.authorSchouten, Jeroen
dc.contributor.authorRoberts, Jason A
dc.contributor.authorLipman, Jeffrey
dc.contributor.authorTacey, Mark
dc.contributor.authorTimsit, Jean-François
dc.contributor.authorLeone, Marc
dc.contributor.authorZahar, Jean Ralph
dc.contributor.authorDe-Waele, Jan J
dc.date.accessioned2023-01-25T08:30:27Z
dc.date.available2023-01-25T08:30:27Z
dc.date.issued2015-12-23
dc.description.abstractAntimicrobial de-escalation (ADE) is a strategy to reduce the spectrum of antimicrobials and aims to prevent the emergence of bacterial resistance. We present a systematic review describing the definitions, determinants and outcomes associated with ADE. We included 2 randomized controlled trials and 12 cohort studies. There was considerable variability in the definition of ADE. It was more frequently performed in patients with broad-spectrum and/or appropriate antimicrobial therapy (P = .05 to .002), when more agents were used (P = .002), and in the absence of multidrug-resistant pathogens (P < .05). Where investigated, lower or improving severity scores were consistently associated with ADE (P = .04 to <.001). The pooled effect of ADE on mortality is protective (relative risk, 0.68; 95% confidence interval, .52–.88). Because the determinants of ADE are markers of clinical improvement and/or of lower risk of treatment failure this effect on mortality cannot be retained as evidence. None of the studies were designed to investigate the effect of ADE on antimicrobial resistance.
dc.identifier.citationTabah A, Cotta MO, Garnacho-Montero J, Schouten J, Roberts JA, Lipman J, et al. A Systematic Review of the Definitions, Determinants, and Clinical Outcomes of Antimicrobial De-escalation in the Intensive Care Unit. Clin Infect Dis. 2016 Apr 15;62(8):1009-1017.
dc.identifier.doi10.1093/cid/civ1199
dc.identifier.essn1537-6591
dc.identifier.pmid26703860
dc.identifier.unpaywallURLhttps://academic.oup.com/cid/article-pdf/62/8/1009/16789133/civ1199.pdf
dc.identifier.urihttp://hdl.handle.net/10668/9680
dc.issue.number8
dc.journal.titleClinical infectious diseases : an official publication of the Infectious Diseases Society of America
dc.journal.titleabbreviationClin Infect Dis
dc.language.isoen
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.organizationHospital Universitario Virgen Macarena
dc.page.number1009-1017
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.pubmedtypeReview
dc.pubmedtypeSystematic Review
dc.relation.publisherversionhttps://academic.oup.com/cid/article-lookup/doi/10.1093/cid/civ1199
dc.rights.accessRights Restricted Access
dc.subjectde-escalation
dc.subjectresistance
dc.subjectstewardship
dc.subjectstreamlining
dc.subject.decsMortalidad
dc.subject.decsRiesgo
dc.subject.decsRiesgo
dc.subject.decsEstudios de cohortes
dc.subject.decsInsuficiencia del tratamiento
dc.subject.decsRevisión sistemática
dc.subject.decsIntervalos de confianza
dc.subject.decsTerapéutica
dc.subject.decsPacientes
dc.subject.meshAnti-Bacterial Agents
dc.subject.meshBacterial Infections
dc.subject.meshClinical Trials as Topic
dc.subject.meshCohort Studies
dc.subject.meshCross Infection
dc.subject.meshDrug Resistance, Microbial
dc.subject.meshHumans
dc.subject.meshIntensive Care Units
dc.subject.meshSeverity of Illness Index
dc.subject.meshTreatment Outcome
dc.titleA Systematic Review of the Definitions, Determinants, and Clinical Outcomes of Antimicrobial De-escalation in the Intensive Care Unit.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number62
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format